OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
17090060

Dong-A ST Co Ltd

PharmaceuticalsVerified

Dong-A ST Co Ltd exhibits a capital structure with a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.52, suggesting it can cover its short-term obligations with its current assets. However, the company's cash and equivalents amount to 38,841,000,320 KRW, which is significantly lower than its long-term debt of 537,055,206,800 KRW, resulting in a negative net cash position after subtracting total debt. Profitability metrics for Dong-A ST Co Ltd are weak, with a return on equity of -4.45% and a return on assets of -2.02%. These figures indicate that the company is not generating returns that exceed its cost of capital, which is a concern for investors. The company's operating income is negative at -17,411,817,770 KRW, and its net income is also negative at -28,592,457,010 KRW, reflecting a challenging financial performance. The company's revenue is primarily derived from its domestic and overseas markets, including Brazil, Turkey, and Cambodia. However, the financial snapshot does not provide specific revenue concentrations by segment or geography, making it difficult to assess the extent of geographic or product diversification. The company's exposure to international markets may introduce additional risks, such as currency fluctuations and regulatory changes. Dong-A ST Co Ltd's growth trajectory is uncertain, as the company is currently reporting negative operating and net income. The financial data does not provide specific outlook figures for the current or next fiscal year, but the negative profitability metrics suggest a need for strategic improvements to achieve sustainable growth. The company's capital expenditure of -35,628,250,630 KRW indicates a reduction in investment, which may impact future growth potential. The company's risk assessment highlights medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company's dilution risk is assessed as low, suggesting that there is minimal threat to shareholder value from new share issuances. However, the company's negative net income and operating cash flow may necessitate future financing activities that could affect dilution risk. Recent events and filings for Dong-A ST Co Ltd do not provide specific details on recent developments, but the company's financial performance and risk assessment suggest a need for close monitoring. The company's negative net income and operating income, combined with its high debt levels, may lead to increased scrutiny from investors and analysts. The company's ability to improve its financial performance and manage its debt will be critical for its future success.

30-day price · 170900-3650.00 (-8.3%)
Low$38200.00High$47500.00Close$40500.00As of22 May, 00:00 UTC
Profile
CompanyDong-A ST Co Ltd
Ticker170900.KS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Dong-A ST Co Ltd is a Korea-based company primarily engaged in the production and sale of pharmaceuticals, including gastric mucosal protective agents, antihistamines, and diagnostic reagents for hepatitis, as well as medical devices such as implants for artificial joint and maxillofacial surgery.

Classification. Dong-A ST Co Ltd is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry, with a confidence level of 0.92.

Dong-A ST Co Ltd exhibits a capital structure with a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.52, suggesting it can cover its short-term obligations with its current assets. However, the company's cash and equivalents amount to 38,841,000,320 KRW, which is significantly lower than its long-term debt of 537,055,206,800 KRW, resulting in a negative net cash position after subtracting total debt. Profitability metrics for Dong-A ST Co Ltd are weak, with a return on equity of -4.45% and a return on assets of -2.02%. These figures indicate that the company is not generating returns that exceed its cost of capital, which is a concern for investors. The company's operating income is negative at -17,411,817,770 KRW, and its net income is also negative at -28,592,457,010 KRW, reflecting a challenging financial performance. The company's revenue is primarily derived from its domestic and overseas markets, including Brazil, Turkey, and Cambodia. However, the financial snapshot does not provide specific revenue concentrations by segment or geography, making it difficult to assess the extent of geographic or product diversification. The company's exposure to international markets may introduce additional risks, such as currency fluctuations and regulatory changes. Dong-A ST Co Ltd's growth trajectory is uncertain, as the company is currently reporting negative operating and net income. The financial data does not provide specific outlook figures for the current or next fiscal year, but the negative profitability metrics suggest a need for strategic improvements to achieve sustainable growth. The company's capital expenditure of -35,628,250,630 KRW indicates a reduction in investment, which may impact future growth potential. The company's risk assessment highlights medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential liquidity constraints. The company's dilution risk is assessed as low, suggesting that there is minimal threat to shareholder value from new share issuances. However, the company's negative net income and operating cash flow may necessitate future financing activities that could affect dilution risk. Recent events and filings for Dong-A ST Co Ltd do not provide specific details on recent developments, but the company's financial performance and risk assessment suggest a need for close monitoring. The company's negative net income and operating income, combined with its high debt levels, may lead to increased scrutiny from investors and analysts. The company's ability to improve its financial performance and manage its debt will be critical for its future success.
Key takeaways
  • Dong-A ST Co Ltd is experiencing negative profitability, with a return on equity of -4.45% and a return on assets of -2.02%.
  • The company's liquidity position is moderate, with a current ratio of 1.52, but it has a negative net cash position after subtracting total debt.
  • The company's capital expenditure is negative, indicating a reduction in investment, which may impact future growth.
  • The company's risk assessment highlights medium liquidity risk and low dilution risk.
  • The company's financial performance and risk profile suggest a need for strategic improvements to achieve sustainable growth.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$808.78B
Gross profit$361.10B
Operating income-$17.41B
Net income-$28.59B
R&D
SG&A
D&A
SBC
Operating cash flow$27.78B
CapEx-$35.63B
Free cash flow-$48.17B
Total assets$1.41T
Total liabilities$769.33B
Total equity$642.71B
Cash & equivalents$38.84B
Long-term debt$537.06B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$642.71B
Net cash-$498.21B
Current ratio1.5
Debt/Equity0.8
ROA-2.0%
ROE-4.5%
Cash conversion-97.0%
CapEx/Revenue-4.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric170900Activity
Op margin-2.2%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin-3.5%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin44.6%47.8% medp25 27.6% · p75 68.9%below median
CapEx / revenue-4.4%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity84.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Observations
IR observations
Mean price target61,244.90 KRW
Median price target60,000.00 KRW
High price target64,761.91 KRW
Low price target59,047.62 KRW
Mean recommendation1.62 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count5.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2,883.33 KRW
Mean revenue estimate828,115,710,000 KRW
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 15:39 UTC#5cac88e0
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 15:41 UTCJob: 7b2067e9